Search

Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

U.S. FDA grants Breakthrough Therapy designation for MASH

Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis

Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US

The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes

Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance’s® effects following an acute myocardial infarction

Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Full results from EMPERIAL exercise ability trials presented

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

IASLC NACLC 2020: Boehringer Ingelheim Presents New Data | BI US

BI announces new data for GILOTRIF®, affirming its activity in SCC of the lung with findings presented at the IASLC 2020. View ISI, PI and Med Guide.

Interchangeable Biosimilar Now on Express Scripts® Formulary

Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary

Jardiance® (empagliflozin) Proven to Reduce Risk of Cardiovascular Death | BI US

Find out more about how the use of JARDIANCE has proven to reduce the combined relative risk of cardiovascular death and hospitalization for heart failure by 25%.

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers